Comorbidity, iron overload and HFE variants: A new prognostic complex in MDS?

European Journal of Clinical Investigation

Volumn 39, Issue 12, 2009, Pages 1112-1113

  Valent, P ^a,b   Sperr, W R ^a,b   Fodinger M ^c   Kundi, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HFE PROTEIN;

BLOOD TRANSFUSION; COMORBIDITY; FERRITIN BLOOD LEVEL; GENETIC IMMUNIZATION; HEART DISEASE; IRON OVERLOAD; LETTER; LIVER DISEASE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS;

DISEASE-FREE SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON OVERLOAD; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL;

EID: 70449465412     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02196.x     Document Type: Letter

References (13)

1. Bennett JM, Komrokji RS. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology 2005 10 : 258 269.
2. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007 31 : 727 736.
3. Nimer SD. Myelodysplastic syndromes. Blood 2008 111 : 4841 4851.
4. Cazzola M, Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N Engl J Med 2005 352 : 536 538.
5. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005 23 : 7594 7603.
6. Várkonyi J, Tarkovács G, Karádi I, Andrikovics H, Varga F, Demeter J et al. High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. Acta Haematol 2003 109 : 64 7.
7. Várkonyi J, Demeter J, Tordai A, Andrikovics H. The significance of the hemochromatosis genetic variants in multiple myeloma in comparison to that of myelodysplastic syndrome. Ann Hematol 2006 85 : 869 871.
8. Nearman ZP, Szpurka H, Serio B, Warshawksy I, Theil K, Lichtin A et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 2007 82 : 1076 1079.
9. Várkonyi J, Andrikovics H, Tordai A. Hemochromatosis gene mutation - could it be a disease marker for myelodysplasia? Leuk Res 2009 33 : 201 202.
10. Zipperer E, Pelz D, Nachtkamp K, Kuendgen A, Strupp C, Gattermann N et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009 94 : 729 732.
11. Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nösslinger T, Stauder R et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core data set of 582 patients of the Austrian MDS Working Group. Ann Oncol 2009 in press.
12. Wang R, Gross CP, Halene S, Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 2009 in press.
13. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997 89 : 2079 2088.